AstraZeneca Pursuing FDA Approval for EGFR-MET Combo in Tagrisso-Resistant NSCLC Patients

AstraZeneca is pursuing FDA approval for a combined treatment of Tagrisso and savolitinib targeting EGFR-MET positive non-small cell lung cancer patients resistant to Tagrisso, with oncologists at the European Society for Medical Oncology Congress calling it a new standard of care.

This Wire brief sits within Fusion42's coverage of Biotech.